C H A I R ' S P R E FAC E
Seven years ago, a group of international experts foresaw an emerging sea of change in how intellectual property in the life sciences is understood. This group, which I have had the privilege to lead, realized that governments, industry, At the centre of the International Expert Group's findings is the recognition that we, in high-, middle-and low-income countries, need to create new organisations to repair the lack of trust existing between those who participate in biotechnology innovation systems, whether as creator, user or manager. Putting our actions behind our words, we have created a new entity, The Innovation Partnership, or TIP (www.theinnovationpartnership.org), a non-profit consultancy with the mission of building this trust through training, independent research and the provision of strategic advice.
Through TIP, the International Expert Group reaches out to indigenous, national and international communities to develop the tools and knowledge necessary for all to benefit from biotechnological innovation in the future.
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E X E C U T I V E S U M M A R Y OV E R V I E W
Intellectual property occupies a central position in the biotechnology innovation system, the expected source of new medicines, foods and bio-energy. An international and interdisciplinary research team has convened for the last seven years in an attempt to better understand the mechanisms of intellectual property in biotechnology innovation, and to suggest improvements to the role of intellectual property in that system. This report represents the research team's core finding and recommendations.
The core finding is that policy-makers and business leaders must give shape to a new era of intellectual property to stimulate innovation and broaden access to discoveries. The current system, 'Old IP,' rests on the belief that if some intellectual property (IP) is good, more must be better. But such thinking has proved counterproductive to industry, which in health fields has seen declining levels of innovation despite increasing stakes in intellectual property. The era of Old IP has also proved counterproductive to the world's poor who await advances in health and agriculture long available to the global elite.
The International Expert Group concluded that a 'New IP' era that focuses on cooperation and collaboration is slowly emerging. Intellectual property is meant to assist in this process by encouraging cooperation among various brokers and stakeholders. The best innovative activity occurs when everyone -researchers, companies, government and NGOsworks together to ensure that new ideas reach the public, but are appropriately regulated and efficiently delivered to those who need them.
To make the transition to New IP, several things are needed:
Greater trust between actors: A lack of trust has blocked collaborations to deliver medicines to the world's poor, has led to ineffective legislative reform and has delayed the rapid Cross-cutting thinking: IP has too long been looked at in isolation from other elements in the innovation system, leading to a poor understanding of IP's role in innovation.
Researchers need to work across disciplines and bring we want from innovation and how to measure it, we will not break out of the vicious cycle of Old IP.
B A S I C C O N C E P T S
Old IP is the current, but waning era of IP, in which companies and universities seek ever greater amounts of IP in order to protect themselves from others. It involves constructing increasingly higher walls around knowledge and controlling it tightly.
New IP is the emerging era of IP in which IP is understood within the entire context of innovation. It stresses sharing and collaboration instead of increased protection, leading not only to greater levels of innovation, but better access to new products and services.
Intellectual property (IP) is a way in which a government
gives power to a person -the IP holder -to control how certain bits of knowledge will be used. A patent gives its holder the ability to control the use of the inventions. Inventions are things such as mousetraps, medicines or novel stem cells.
Inventions are also ways of doing things, such as how to mix chemicals together or how to insert a gene into a cell's DNA.
Copyrights cover works of art, plays, music, computer programs and databases, and give their holder a specific power:
to prevent others from copying the way they expressed themselves in these works, but not in the idea of the work itself.
Trademarks provide their holders with the ability to stop others from using names (Nike or Coke, for example), symbols (think of McDonald's arches) or other logos, shapes or sounds to sell products or services.
Biotechnology is the use and manipulation of living organisms and biological processes to meet various industrial, environmental, health and agricultural needs. While wine, cheese, and beer may be among the oldest forms of biotechnology, modern biotechnology involves the deliberate and measured manipulation of genes, proteins and other components of life to produce new products and services. These include the controversial -such as genetically-modified plants and stem cells originating from human embryos -and the well accepted and critical, such as the production of life-saving insulin for diabetics through genetically-modified bacteria.
An innovation system, described by the person who coined the term, is a local, national or international "network of institutions in the public and private sectors whose activities and interactions initiate, import, modify and diffuse new technologies." 1 Innovation systems are more circular than linear; there is no one 'beginning' and 'end' to innovation.
One person -a user, researcher or company -picks up where the last left off.
A C H A N G E O F E R A W h y i s t h e O l d I P E ra C o m i n g t o a n E n d ?
Old IP has its roots in two developments in 1980: a US Supreme Court decision to grant a patent over geneticallymodified bacterium 2 and a US statute that told universities to patent and commercialise publicly-funded scientific research. 3 Soon, patents were extended to software programs, entire animals and plants and now even ways to save on income tax. Other places, such as Japan and Europe, wishing to benefit from the biotechnology and information technology boom, brought their IP laws into line with those of the US. 4 
To w a rd s a N e w I P E ra
The era of Old IP had multiple flaws. It failed to recognize that knowledge leads best to new products and services if shared. 5 It wrongly assumed that companies obtain IP to protect their inventions from being copied rather than to trade or enhance their reputations. 6 It wrongly presumed that if a company has a patent right it could actually use it to prevent others from copying the invention. 7 It exaggerated the importance of patents; 8 other impediments -such as income tax rules, regulations and political and cultural understanding -may often be more important. 9 Research also showed that it was unclear whether patents actually increase inventiveness and dissemination. 10 And last, Old IP failed to come to grips with the reality of public health and public health care systems.
Because of these flaws, the era of Old IP is drawing to a 
S I X T H E M E S FO R T H E N E W I P E R A
The International Expert Group set out to build a framework through which to understand the emerging New IP era. They concluded as follows:
On trust: One of the most glaring failures of Old IP is that it continues to undermine trust. Trust among all of the players involved is essential to meeting the challenge of remaking this system so that research networks result in the creation, sharing, improvement and combination of knowledge. For now, governments do not have the capacity to step back and facilitate relationship-building. Outsiders must fill this role. On new models: Industry, governments and universities can develop new models to mobilize the innovation system to produce better results. These models will stress sharing over hoarding, and stress partnership over barriers.
Examples of what these models will look like already exist. countries lack critical infrastructure such as access to highspeed internet. And lastly, a country must also manage its biotechnological innovation system to get the greatest benefits in economic, health, agricultural and industrial needs.
On cross-cutting thinking: More attention needs to be paid to understanding how IP contributes to the overall function of the innovation system rather than deal with it in isolation.
Once we better understand what most spurs innovation, we can ensure that our discussions stay focused on the potential of biotechnology to address health, agricultural and industrial needs.
On data and metrics:
There is a lack of empirical data on such critical questions as to whether, how and when IP increases levels of investment in research and development.
Does IP encourage or retard development in low and middle income countries? Does it facilitate or hinder the dissemination of new products and services? This data does not exist because IP is rarely the principal driving innovation. In addition, there is a lack of common standards in data collection among agencies and among countries. There is a particular dearth of data with respect to university and other public sector technology transfer and dissemination.
RECOMMENDATIONS
The International Expert Group agreed on the following actions to be taken by governments, patent offices and universities and the scientific community.
1.GOVERNMENTS SHOULD TAKE THE LEAD ON THE FOL-
LOWING ACTIVITIES:
1.1. They should pay at least as much attention to the environment in which innovation takes place -including regulation of the health and environmental effects of biotechnology, the independence of the judicial system, laboratory facilities, training and marketplace regulation -as they do to IP.
1.2.
They should encourage, financially and intellectually, the creation of independent trust builders to mediate disputes and encourage dialogue between actors and provide training, particularly to lower income countries.
1.3. They should support independent organisations to engage indigenous and local communities at a grass-roots level in training on and policy development in relation to IP, the protection of indigenous knowledge and methods to share that knowledge while respecting the rights and autonomy of those peoples.
1.4.
They should standardize the collection of important science and technology measures to permit comparisons of different models of managing IP.
1.5.
Governments with public health care systems should work with industry, funding bodies and universities to develop a PPP to manage health-related data to encourage collaborations and innovation.
1.6.
Government funding agencies should target the development of novel and sustainable business models and their implementation, particularly in low and middle income countries. In particular, funding should be made available to support pilot projects on commercializing and disseminating low and middle income technologies.
AS CUSTODIANS OF THE PATENT SYSTEM, PATENT OFFICES AROUND THE WORLD SHOULD DO THE FOLLOWING:
2.1. They should collect patent-related information in a standard form and make this available to the public for free. Data should include information that will assist in assessing patent landscapes in targeted areas of technology, such as essential medicines.
2.2.
In addition to collecting patent information, they should collect data on the type and major terms of license agreements.
They should establish policy branches to investigate
ways to make data more available, assist in patent landscaping and disseminate information about the patent system.
THE PRIVATE SECTOR SHOULD TAKE RESPONSIBILITY FOR THE FOLLOWING:
3.1. They should support the creation of trust builders and agree to submit disputes to them for mediation.
3.2.
They should support the work of trust builders in organising workshops and training programmes through which stakeholders can discuss and exchange views on IP policy.
3.3.
Leading private sector institutions in high, middle and low income countries should establish an independent, non-profit technology assessment organization to evaluate new biotechnology products and services originating in low and middle income countries and by indigenous and local communities.
3.4.
Together with business, law and economics experts, they should develop new and sustainable business models of developing, commercializing and disseminating biotechnology products and services that are attuned to local needs and conditions. This includes greater collaboration with public sector initiatives.
3.5. They should be transparent about the patents they hold and where they are registered, and collaborate with patent offices in building publicly-available databases of this information.
THE MEDIA HAS AN IMPORTANT ROLE TO PLAY IN IP POLICY AS WELL:
4.1. The media should develop a science policy news beat to facilitate general knowledge of science and technology issues and encourage coverage of the role of science on economic and social welfare.
UNIVERSITIES AND THE SCIENTIFIC COMMUNITY SHOULD DO THE FOLLOWING:
5.1. Universities should establish clear principles relating to the use and dissemination of their IP that includes ensuring greater access and the use of licensing provisions that make it easy to conduct research and development on products needed by low and middle income countries.
5.2.
They should develop new measures of the success of technology transfer, development and social investment that correspond to social and economic return.
5.3.
Business schools should include low and middle income country conditions and opportunities in their curriculum and should develop programmes through which their students can provide business planning assistance to low and middle income country entrepreneurs.
5.4.
Universities in high income countries should collaborate with those in low and middle income countries to create educational opportunities at the doctoral and post-doctoral levels through which scientists maintain links with their countries of origin and conduct research focused on the needs of those countries. Universities in high income countries should encourage those of its professors from the Diaspora to assist their countries of origin through supervision of students, joint research projects, conducting peer review and so on.
5.5.
Researchers should analyse questions of IP within the larger context of IP and innovation systems. To do so, they should use analytical tools that provide a broader, inter-disciplinary perspective on IP and innovation.
T H E T H E M E S I N P R A CTICE: A V I E W O F N E W I P
Highlighting six themes, the International Expert Group sketched out three representative ways for public and private sector decision-makers to modify IP systems.
First, decision-makers could place their emphasis on maximizing short-to medium-term levels of biotechnological innovation. The central challenge of this in the New Era of intellectual property will be to increase collaboration and the flow of basic scientific knowledge. Public sector policy-makers should focus on building collaborative relationships between public and private sector actors. Some of these relationships will rely on private financing and the appropriation of products and services emanating from these collaborative efforts while at the same time ensuring that basic knowledge and data remain free to users. Building collaborations requires, however, trust and communication.
Public and private sector actors need to develop connections to increase communication and trust. Drawing on the expertise of independent "trust builders" would be a start. A R e p o r t f r o m t h e I n t e r n a t i o n a l E x p e r t G r o u p o n B i o t e c h n o l o g y , I n n o v a t i o n a n d I n t e l l e c t u a l P r o p e r t y I n t e l le c t u a l P ro p e r t y In short, Old IP understood patents, copyrights and trademarks to be simply mechanisms that permitted a company, having invested in research and development, to recoup its costs and make a profit before others are allowed to copy its idea. This understanding has several flaws, however.
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T H E P R O B L E M O F O L D I P
The upcoming New IP era will build on what we learned from its predecessor. By the early 1990s, it was clear that the majority of industrialized country corporate assets were no longer tangible such as factories, land and inventory, but intangible such as reputation, customer lists, credit and institutional knowledge. This was particularly true in hightechnology companies such as the computer industry, and biomedical companies. Knowledge in these industries is hard to contain. Unlike the physical things that we make using our knowledge -a new hybrid variety of wheat, a plate of pasta, or the prize for winning a marathon -knowledge is elusive: it is hard to pin down, hard to trade, hard to control and hard to value. As uncertainty in business means higher risk, those industries that depended most on knowledge wanted to pin it down as best they could. Their reaction was, to protect themselves by building more and higher walls around knowledge.
This time -in the 1980s and 1990s -the walls were made of laws rather than of brick or stone.
The Old IP era grew out of this reliance on legal rather than physical power. IP became the mechanism of choice to maintain control over the elusive intangible assets that lay at the heart of most companies and, hence, most industrialized economies. Through IP, companies could control who used inventions when and in what combinations. 10 This control gave assurance to investors in these companies that the companies could protect themselves from competitors. This was, however, only part of the story. As a result of increased globalization, the control over intangible assets needed was not only local or national, but in any market around the globe in which one hoped to eventually compete. Thus, some IP at home was good, but more was better at home and around the world. This has been the logic of Old IP. Second, it assumes that most companies actually use IP to protect their inventions from being copied. This turns out to be only part of the story. Companies increasingly obtain patent rights, for example, for strategic reasons. These include using patents offensively to block others from entering the market by creating mine fields around a company's technology. These patents are wasteful and often of lower quality. 17 Other strategic uses include using patents to trade with other companies, obtaining patents simply to show that one is serious to outside investors or acquiring patents to increase their reputation as innovators.
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Together, these strategic uses of patents point to the evolving nature of IP rights and the need to adapt policy to changing business practices.
While some companies seek patents for reasons other than protecting investments, other organisations, particularly in low-and middle-income countries, do not even bother to patent their inventions because they cannot afford to defend them should a high-income country company infringe it. Research institutions and small enterprises in lower income countries feel that they cannot participate in the IP system since no potential infringer would believe they would be pursued. These institutions and enterprises are the have-nots of the IP system.
Third, Old IP presumes that if a company has a patent right it can actually use it to prevent others from copying the invention. The reality is, however, that there is a significant gap between the rights the law says one has and what one can actually do in the real world. In the first place, there is the obvious problem of being able to identify cases of copying.
Even if one can do so, enforcing patent rights through the courts is expensive -between $1 and $3 million in the US. 
U N D E R S TA N D I N G I P SY S T E M S
Once we understand that IP affects relationships between people acting within an innovation system, we can examine more carefully how it does so. Certainly the legal rules sur- Not only do we accept widespread violations of the letter of the law, we actually celebrate it. A study of US academic scientists demonstrated that, in conducting their research, they routinely ignored patent rights. 44 Far from being decried, this has been taken as evidence that the IP system works and does not limit creativity. In fact, companies often want academics to conduct research on their inventions -even without consent -since the academics may find something that increases the value of their patents.
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What this points to is that IP law should only be the beginning, not the end, of any analysis of how IP affects actors working within an innovation system. As discussed above, how actors behave in the face of IP rights is perhaps more critical to what is innovated and used than the law itself.
Beyond simply ignoring the law, actors also manipulate it in various ways. We have previously seen that companies frequently obtain patents not to protect their inventions, but in order to trade or to set IP traps for potential competitors.
Actors can, however, also act more constructively. They can, for example, allow others to use their inventions through a contract or by working on a collaborative research project.
Patents also affect the behaviour of competitors or users.
Competitors may invest in technologies to circumvent a patented invention or hire lawyers to determine whether putting a product on the market will infringe another's patent. Recognizing the need to bring disciplines together is easy.
Putting them together has proven extremely difficult. As noted by one writer, "One obstacle to improving our understanding is that innovation has been studied by different • They would construct a single framework for understanding the role of IP systems within biotechnological innovation systems that was common to all disciplines, industry, government, and the public and that could help answer a wide set of questions.
• The framework would integrate a large set of quantitative data (e.g., statistics, polls and so on) and qualitative data (such as interviews, case studies and expert opinion) to overcome the lack of empirical knowledge on IP systems.
• The framework would be validated through the participation of experts in academia, industry, government, the research community, and the public through peer-review workshops, interviews and a reading of scholarly and policy publications.
The construction of this framework followed five steps. 
Findings
Intellectual property should be understood horizontally, that is, as cutting across academic disciplines, government and industry departments and fields.
Tools are needed in order to permit public and private sector decision-makers to better use IP systems.
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R E C O M M E N DAT I O N S FO R M OV I N G TOWA R D N E W I P
Drawing on the framework it developed, the International Expert Group mapped out how public and private sector decision-makers can proactively plan for the approaching era of New IP. In doing so, they recognized the importance of taking a holistic approach to the role of IP within innovation systems. That is, rather than analyse the small sub-components of the IP system in isolation, the international experts adopted the standpoint of an 'intellectual architect', a person who sees not only a country's "innova- 
T h e I m p o r t a n ce o f Tr u st
One of the most glaring failures of Old IP is its continuing outcome of undermining trust. The mentality of Old IP -that IP is to be held tightly and not shared -has led to fear of it not being respected and to distrust of those who hold it. The research carried out by the International Expert Group found that a lack of trust lay at the bottom of virtually all major controversies surrounding biotechnological innovation.
Examples include the following:
Brand-name pharmaceutical companies and NGOs involved in delivering health services to low-and medium-income countries distrust one another so much that they avoid becoming involved in otherwise worthwhile projects that would require collaboration. 57 Companies with new biotechnology products distrust the decisions that public-health administrators make on how to introduce, monitor, and pay for new health services while the public officials distrust the motives of those companies. 58 Indigenous communities distrust their own governments' intentions when it comes to protecting their traditional knowledge, fearing that the central government will take away their rights and culture. 59 
Staff members of the World Intellectual Property
Organization so distrusted their Director General that he was forced to resign. 
B OX A
In order to supply medications to fight HIV/AIDS, malaria and tuberculosis in low-and medium-income countries, France decided to create a fund out of an airplane ticket tax. In 2006, France, together with other countries such as Brazil, the UK, philanthropic foundations and NGOs, created UNITAID, an international governmental organisation housed by the World Health Organization. While UNITAID's principal function is to assist organisations on the ground to purchase medications, it also wanted to ensure that the medicines needed were available and reasonably priced. It therefore began a pilot project to build a patent pool around fixed-dose combinations and paediatric doses of anti-AIDS drugs. With the expert assistance of The Innovation Partnership and the participation of NGOs, UNITAID will sponsor a new non-profit agency to license the right to manufacture these drugs from brandname pharmaceutical companies and provide those licenses to manufacturers and distributors in low-and mediumincome countries. Through this process, drugs in a form not otherwise available will be delivered to those most in need.
A lack of trust is particularly evident in the relationship between indigenous peoples and their governments.
Governments and researchers have concentrated much more on using the natural resources and, on some occasions, the knowledge of indigenous peoples than on respecting their autonomy. In order to build trust, governments will need to support the building of autonomous indigenous institutions with the capacity to sustain and develop indigenous knowledge and to apply their laws and practices, particularly when interacting with non-indigenous groups, including researchers, corporations and governments. They will also need to develop a legal framework in which to protect the autonomy and land rights of indigenous people. 63 Similarly, low-and middle-income countries with high levels of genetic diversity, such as Brazil, Indonesia and Kenya, will need to balance economic development based on the use of natural resources (particularly when involving indigenous people)
with the needs of communities. Local economic development and targeted research in those countries should aim to generate sufficient economic resources to lead to the conservation of their biological and cultural diversity. 
Communications
Communication is a critical ingredient to building trust.
During the era of Old IP, industry and NGOs talked past one another, failing to understand the other's concerns. 65 Further, communication failures were a major cause for With what is now known -thanks largely to the study of the failures of Old IP -industry, governments, and universities can develop new models of how to mobilize the innovation system to produce better results. These models will stress sharing, not hoarding, and partnership, not barriers.
Examples of what these models will look like already exist.
These include the following efforts:
• A PPP to develop a new HIV vaccine through the International AIDS Vaccine Initiative (IAVI); 77 • A PPP devoted more generally to vaccines through the GAVI Alliance;
• Partnerships between each of Sanofi and GSK with DNDi;
• A patent pool to be established by UNITAID for anti-retroviral drugs to combat HIV/AIDs;
• The Structural Genomics Consortium, a PPP aimed at discovering the structure of proteins and making these structures freely available to all (see BOX B);
• A university initiative to bring together all patents relating to agricultural biotechnology that may be of use in developing food for low-and middle-income countries (PIPRA);
• A fund set up by Italy, Canada, Norway, Russia and the United Kingdom that will pay for the delivery of a vaccine against pneumococcal virus;
• The Human Genome Project, an international collaboration of public research centres, funded by government agencies, that sequenced the entire human genome and placed that information in a free, publicly-available database;
• The Single Nucleotide Polymorphism (SNP) Consortium, an international collaboration of foundations, industry, and public research centres to create a free, public database of single mutations of interest in health research.
BOX B
The Structural Genomics Consortium (SGC) is a true public- these machines off the market 79 -until it realized that it makes more money from video and now from DVD rentals than it does from ticket sales at theatres. 80 The pharmaceutical industry continues to call for increased patent rights -for example, longer terms and automatic injunctions -despite the fact that the last time they did so (in Canada), the promised increased investment never fully materialized and has, in fact, sunk to old levels. 81 The pharmaceutical industry has begun, however, to realize that its business models no longer serve themselves or the What is now required is the political will and business capacity to harness the benefits of this technology.
A prerequisite to creating new business models for biotechnology, bringing forth technology developed in low-and middle-income countries and developing and using promising technology by the public sector, is leadership in establishing clear goals for health, agricultural and industrial innovation. Europe has largely decided, for ethical reasons, to withhold patents over the cells, this seems to have little or no effect on the use of embryonic stem cells in research on the continent. 97 Conversely, in the US, where patents continue to be granted over stem cells, a federal ban on funding embryonic stem cell research has slowed research.
C ro s s -C u t t i n g T h i n k i n g
Similarly, the continuing debate over whether commercial enterprises should be permitted to patent and profit from government-supported research is often debated separately from discussions of how best to disseminate this research. Some consider it unfair that a private actor should be able to appropriate the benefits of something created through public funding. If, however, the models of dissemination developed through Recommendations 7, 8, and 9 require private participation, it may not only be fair but appropriate to accord some IP rights to private actors in order to facilitate that dissemination. Of particular concern to international governmental organisations and NGOs operating globally to provide medicines to the world's poor is better information on whether, where and how those medicines are subject to patent rights. Current patent databases make such searches difficult. Industry can assist in this by being more transparent about the patents they hold, including those over pharmaceutical and biotechnological products. Patent examiners, as they review patent applications could, in addition, indicate in the database whether the invention being examined is related to key medicines. Further, information could be collected on whether these patents are subject to any licences and, if so, the prin- The International Expert Group selected three strategies to examine, each revolving around separate goals: 1) to maximize short to medium term levels of biotechnological innovation; 2) to build and maintain the scientific infrastructure necessary to carry on biotechnological innovation; and 3)
E X A M P L E S O F P O L I CY S T R AT E G I E S I N T H E N E W I P E R A
to maximize access to existing and future biotechnology.
While not mutually exclusive, each strategy focuses on a key policy area. We present a brief overview of each strategy here, leaving the details to online materials.
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M a x i m i z i n g S h o r t t o M e d i u m Te r m I n n ova t i o n
The central challenge of ensuring innovation in the era of New IP will be to increase collaboration and the flow of basic scientific knowledge. Where knowledge hoarding is common in the Old IP era, the International Expert Group foresees that New IP will usher in a period marked by the creation of new partnerships and other forms of collaboration. Given this, public sector policy-makers would be wise to focus on building collaborative mechanisms through which to link public and private sector actors. These should be designed to ensure that basic knowledge and data remain free to use.
That is, while individual companies will be able to commercialise particular molecules or plants developed through collaborations, the new research and data they generate in doing so will remain a shared resource. Recommendations 7, 8 , and 9 are particularly apt in addressing this need.
Building collaborations requires, however, both trust and would be a start.
The expert group further noted the lack of managers with a specific understanding of biotechnology. Good management, more than good IP, is essential to the success of any biotechnology enterprise, whether in the public or private sector.
Without a large cohort of well-trained and experienced managers, it will be difficult to construct and implement the creative business models that will be necessary in the New IP To achieve all three forms of access requires a holistic approach to policy development. In particular, the IP system should not be viewed in isolation but as part of larger national and international innovation systems. Recommendations 4, 6, and 9 set out the parameters for such an approach. 101 See, generally, www.theinnovationpartnership.org. Soon will be the time to bury Old IP and in its place the era of New IP will begin. By aligning IP policy with democratic values of equity and fairness, as suggested by this report and its recommendations, governments, researchers, universities, industries, and NGOs can embrace the future. 103 Ernst & Young, supra note 43.
A R e p o r t f r o m t h e I n t e r n a t i o n a l Recommendation 17: To better enable patent offices to respond to the needs of the public sector, these offices should establish policy branches that would investigate ways to make data more available, assist in patent landscaping and disseminate information about the patent system.
